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Although some have negated the progress that has been achieved in the last decade, there 
has been steady improvement in the median survivals and two-year survivals as compared 
to trials published and presented from the Ashford Castle, Ireland Meeting in 1983 [l]. In 
that year, the median survivals approximated one year; 2-year survivals were at best 14 
to 17 per cent. There are a number of explanations for this including stage migration and 
selection factors, all of which influence patient entry onto trials. However, better chemo- 
therapeutics with platinum etoposide-based programs (instead of cyclophosphamide 
doxorubicin-based programs) and improved abilities to deliver radiotherapy in concurrent 
or alternating schemes may have contributed to these improved results. 
A major reason to add radiotherapy to combined modality trials in small cell lung cancer 
is the approximately 80% local failure rate with chemotherapy alone. Even with the addi- 
tion of radiotherapy in low doses, the failure rate still approximates 80% and in higher 
doses it remains at roughly 30% [2]. The best local control rate published is 97% after 60 
Gy was used with an infrequently used chemotherapy regimen [3]. The median and 2-year 
survival were too short, perhaps reflecting poor systemic control with this chemotherapy 
program. 
Methods 
Table 1 displays the factors that may influence the relative merits of different schedules 
and strategies in administration of thoracic radiotherapy. Dose must be discussed both in 
terms of physical dose, expressed in rad or Gy, and relative biologic dose, expressed as 
“RET’s” or Gy-10’s for acute effects and “NRET’s” or Gy-3’s for late effects. The relative 
Correspondence to: A.T. Turrisi, 111, M.D., Dept. of Radiation Oncology, The University of Michigan Medical 
Center, Ann Arbor, MI 48109, USA. 
240 
biologic dose is influenced by the fractionation scheme, the time, the dose-per-fraction, the 
program of chemotherapy, and the factors listed in Table 1. Some chemotherapeutic agents 
may cause an increase in adverse effects. The aim of combined modality therapy is to 
provide synergistic or at least additive anti-tumor effects. When certain strategies of thorac- 
ic radiotherapy are employed and with particular chemotherapeutics, such as doxorubicin, 
bleomycin, mitomycin-C, or nitrosoureas, the net effect may produce an increase in lung 
tissue toxicity. The strategy of the successful combined modality trial is to find ways to 
provide increased efficacy against the cancer without causing excess toxicity to normal 
tissues. 
The volume is another important factor that needs attention in lung cancer trials. Al- 
though volumes have increased in lung cancer therapy, no critical analysis shows that 
larger volumes improve survival or significantly enhance local control. Many have in- 
creased the volumes because of the anatomic knowledge of the lymphatics, or their frequen- 
cy of involvement or potential for failure in those sites. Because of the therapeutic successes 
achieved in lymphomas, such as Hodgkin’s disease, which were expanded field radiother- 
apies, the analogy dictates to lung cancer radiotherapy portals. 
The Looney Hypothesis integrated radiotherapy with chemotherapy in novel ways [4]. 
In the laboratory, this resulted in enhanced cure rates. When brought to the clinic, another 
objective sought was reduction of toxicity. Alternating weeks of chemotherapy with weeks 
of radiotherapy allow relatively full doses but commonly requires split-course radiothera- 
py. This strategy has been attempted in small cell lung cancer; however, with the chemo- 
therapeutics used and in the schedules employed, despite increasing the dose from 45 to 
55, and then 65 Gy, 3-year actuarial figures continued to show 70% control, no improve- 
ment in terms of local control [5]. Survival was adequate and comparable to other studies 
of the era, but the French studies that attempted alternating therapy failed to provide the 
desired goal of better local therapy with lesser toxicity [5]. One reason for local failure may 
be inadequate or suboptimal coverage of the tumor bed. Many thoracic radiotherapy 
programs have used posterior spinal cord blocks. In this era, with the use of simulation 
and CT-directed treatment planning systems, both inclusion of target volumes and exclu- 
sion of critical normal tissues can be guaranteed. Over the next decade we will need to focus 
on normal tissue complication. The spinal cord has been the focus of concern in the past. 
Today computerized scans aid in diagnosis and therapy planning. These systems facilitate 
radiation of the target, but also assure protection of critical tissues. Systems are now being 
tested to determine new levels for partial-organ tolerances. Prediction of complication may 
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vary amongst different normal tissues that may have varied dependencies on volume, dose, 
and slope of curves describing specific events. For some tissues, like lung, volume is likely 
to be quite important, perhaps much more important than dose. 
The concept of iso-effects is not new. When different fraction schemes are used, it is 
valuable to be able to compare the relative acute and late effects of various fraction 
schemes. The concepts of nominal standard dose (NSD) and biologic-effective dose (BED) 
draw attention to the fact that the physical dose by itself is an inadequate representation 
of the effect that radiotherapy has on living tissues [6]. Radiation oncologists have under- 
stood that there is a difference between the acute tissues’ response and late effects, but most 
regimens have been designed to balance acute-effect tissue response. The correlation be- 
tween acute effects and late effects is imperfect. However, acute effect may parallel anti- 
tumor effect. In the ideal world, it would be wonderful to have a therapy that produces 
no acute tissue damage, but it may be unrealistic to expect that there will be an absence 
of acute effects that still maintain anti-tumor effects. Today, we are better able to support 
patients through acutely toxic events. 
Standard or conventional dose radiotherapy has presently been established at 60 Gy in 
2-Gy fractions. However, precise control rates in the chest and the exact dose limiting 
toxicity to each of the organs irradiated remain somewhat arbitrarily defined, so many are 
unsatisfied with that, and we plan to attempt to re-establish partial lung tolerances for 
radiotherapy in standard fraction schemes by using 3-D treatment planning. However, 
standard fractionation already lasts for 6 weeks. The prospect of accelerated repopulation 
of cancer cells during these protracted schedules has led many to explore accelerated 
fraction schemes. Hyperfractionation is very good for tumors with no radiobiologic shoul- 
ders. Accelerated fraction schemes have been used to treat small cell lung cancer; however, 
some may want to test a hyperfractionated scheme, particularly if the late effects to lung 
and spinal cord of the accelerated schedules seem excessive [7]. Furthermore, most view 
the late effects that have been achieved with these accelerated schedules to be fairly well- 
tolerated. Table 2 compares the advantages of accelerated versus hyperfractionated 
schemes. In general, there has been a movement away from the use of hypofractionation, 
except for palliation. 
Clinical example 
In 1984, at the University of Pennsylvania, we conducted a trial comparing twice-a-day 
TABLE 2 
Advantages of hyperfractionation and acceleration 
Hyperfractionation Accelerated fractions 
Excellent for sensitive tumors without shoulders Sensitivity relatively less important 
Respects delicate surrounding late normal tissues (i.e. Attends to accelerated “repopulations” 
lung, spinal cord) 
Higher physical dose Lower physical dose increased biologic dose? 
Time relatively unchanged from standard therapy Decreased overall time 
Relatively increased risk of acute toxicity 
242 
radiotherapy used concurrently with platinum etoposide chemotherapy (60 mg/m2 on day 
1, etoposide 120 mgIm2 days 4, 6, and 8 of each cycle); two intense cycles of that chemo- 
therapy were used; the radiotherapy overlapped with the first cycle [7J. There were no 
weekend treatments. Breaks were not allowed in radiotherapy, and, irrespective of the 
Cycle 1 toxicity, Cycle 2 chemotherapy was given in full doses on day 22. Subsequently, 
six alternating cycles of platinum etoposide (PE) and cyclophosphamide, doxorubicin, 
vincristine were alternated. At completion of approximately 6 months of therapy, prophyl- 
actic cranial irradiation was applied to all surviving, completely responding patients. The 
rationale for using the twice-daily radiotherapy was that the small fractions cause relatively 
less damage to surrounding normal tissues with a radiobiologic shoulder, such as lung and 
spinal cord, and even relatively acute-responding tissues, such as esophagus. On the other 
hand, small cell lung cancers without a shoulder were exponentially killed; and thus, did 
not have the opportunity to repair the damage that these relatively small doses per fraction 
provided. Also, since small cell lung cancer has the most prolific growth rate of any solid 
tumor, the potential for tumor growth between fractions of radiotherapy made allowed for 
passage from the relatively resistant S-Phase of the cell cycle to the more sensitive G2-M 
or M-Phase which is more radiosensitive [7]. 
Table 3 displays the PE trials: five twice-a-day radiotherapy studies and two once-a-day 
radiotherapy studies. There appear to be improved outcomes between these trials and older 
cyclophosphamide-based trials. The two-year survival is not dramatic between the daily 
and b.i.d. schedules. A number of factors differ between the trials including: PE-dose 
schedule, timing of radiotherapy, selection criteria, duration of follow-up. The data pre- 
sented show some differences in local control. However, the majority of failures remain 
systemic failures that lead to the largest cause of patient death. In order to clarify some 
of these issues, presently, there is an active ongoing trial in the ECOG, RTOG and SWOG 
that compares 45 Gy given in 3 weeks by a b.i.d. accelerated schedule versus 45 Gy given 
in 5 weeks in a standard schedule employing 1.8-Gy daily fractions. Early endpoints for 
toxicity, response and median survival appear similar; however, the longer-term endpoints 
of 1,2,3 and 5 year disease free and overall survival, as well as local control, need more 
. 
TABLE 3 
Combined thoracic radiotherapy and platinum etoposide trials for limited small cell hmg cancer 





Penn [7l 32 45 Concurrent 3 weeks 48’ 84’ 
ECOG-1 [8] 41 45 Concurrent 3 weeks 36 
NCI-US [9] 35 45 Concurrent 3 weeks 65 
Mayo [IO] 36 48 Split course 6 weeks 40 91 
ECOG-II [l I J 41 45 Alternating 8 weeks 40 
QD studies 
SWOG [12] 154 45 Concurrent 5 weeks 42 _ 
Memorial [13] 35 45 Sequential 45 weeks 46 74 
‘All 4 variant histologies failed locally, only one pure small cell failed locally. 
BID=twice daily; QD=once daily; ECOG=Eastern Cooperative Oncology Group; SWOG=Southwest Coopera- 
tive Oncology Group. 
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TABLE 4 
Relative scales to compare 45 Gy delivered in varied fraction sizes and times 
Institution Fraction (n) Fraction size 
(GY) 
Time (days) RET NRET 
Memorial 18 2.5 30 1546 1029 
SWOG 25 1.8 33 1415 885 
Penn, ECOG-I 30 1.5’ 19 1438 844 
ECOG-II 30 1.5’ 54 1282 193 
‘Twice daily. 
follow-up and patient numbers to better evaluate the merit or risks of altered fraction 
schemes. 
Table 4 displays 4 ways to deliver 45 Gy to the chest, as delivered in 4 reported trials. 
The Nominal Standard Dose methods have been used to compare relative effects, the RET 
provides a relative scale for acute effects, and the NRET provides a relative scale for late 
effects. These scales may have flaws making their absolute values questionable, but they 
provide a reasonable mathematic model offering relative values for comparison of different 
fractionation on time schedules. Most believed the 45 Gy given in b.i.d. fashion was much 
more acutely toxic than the same dose administered once each day in 18-Gy fractions - 
the two schemes used in the Intergroup Trial in the United States. The calculations predict 
very little difference between the two schedules, at least due to the radiotherapy factors (see 
SWOG vs. Penn or ECOG-I, Table 4). Differences may also be influenced by the type of 
and timing with chemotherapy, as well as patient and tumor factors. Only trials will 
determine if “breaks”, time protraction of therapy, provide safer therapy or result in better, 
worse or similar tumor controls. 
Prophylactic cranial irradiation remains a contentious issue. If it is to be used, the 
relative effect of fractionation may be important. Even trials that have applied doses 
between 2000 and 3000 rad in one to three weeks report brain failures of approximately 
20%. Doses using larger dose per fraction that are integrated with chemotherapy in ways 
that allow for an adequate blood/brain barrier protection have resulted in late imaging 
abnormalities and late neurologic toxicities [14-161. There is relatively little information 
of using hyperfractionated schemes in prophylactic cranial irradiation. Since hyperfrac- 
tionation is the best strategy to avoid unfavorable late effects, this may be a useful strategy. 
However, it would tax the patients to travel more frequently. Three-gray or greater frac- 
tions were probably unwise, even when delayed to completion of systemic therapy, 
Perturbations in fractionation, overall time of therapy and integration of chemotherapy 
with local modality affords a rich vein to pursue in clinical research. There are rationales 
to increase effectiveness and decrease toxicity. Both are worthy of further investigation. 
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